Back to Search Start Over

DCRM Multispecialty Practice Recommendations for the management of diabetes, cardiorenal, and metabolic diseases

Authors :
Yehuda Handelsman
John E. Anderson
George L. Bakris
Christie M. Ballantyne
Joshua A. Beckman
Deepak L. Bhatt
Zachary T. Bloomgarden
Biykem Bozkurt
Matthew J. Budoff
Javed Butler
Samuel Dagogo-Jack
Ian H. de Boer
Ralph A. DeFronzo
Robert H. Eckel
Daniel Einhorn
Vivian A. Fonseca
Jennifer B. Green
George Grunberger
Chris Guerin
Silvio E. Inzucchi
Paul S. Jellinger
Mikhail N. Kosiborod
Pamela Kushner
Norman Lepor
Christian W. Mende
Erin D. Michos
Jorge Plutzky
Pam R. Taub
Guillermo E. Umpierrez
Muthiah Vaduganathan
Matthew R. Weir
Source :
Journal of diabetes and its complications, vol 36, iss 2
Publication Year :
2022
Publisher :
eScholarship, University of California, 2022.

Abstract

Type 2 diabetes (T2D), chronic kidney disease (CKD), atherosclerotic cardiovascular disease (ASCVD), and heart failure (HF)-along with their associated risk factors-have overlapping etiologies, and two or more of these conditions frequently occur in the same patient. Many recent cardiovascular outcome trials (CVOTs) have demonstrated the benefits of agents originally developed to control T2D, ASCVD, or CKD risk factors, and these agents have transcended their primary indications to confer benefits across a range of conditions. This evolution in CVOT evidence calls for practice recommendations that are not constrained by a single discipline to help clinicians manage patients with complex conditions involving diabetes, cardiorenal, and/or metabolic (DCRM) diseases. The ultimate goal for these recommendations is to be comprehensive yet succinct and easy to follow by the nonexpert-whether a specialist or a primary care clinician. To meet this need, we formed a volunteer task force comprising leading cardiologists, nephrologists, endocrinologists, and primary care physicians to develop the DCRM Practice Recommendations, a multispecialty consensus on the comprehensive management of the patient with complicated metabolic disease. The task force recommendations are based on strong evidence and incorporate practical guidance that is clinically relevant and simple to implement, with the aim of improving outcomes in patients with DCRM. The recommendations are presented as 18 separate graphics covering lifestyle therapy, patient self-management education, technology for DCRM management, prediabetes, cognitive dysfunction, vaccinations, clinical tests, lipids, hypertension, anticoagulation and antiplatelet therapy, antihyperglycemic therapy, hypoglycemia, nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH), ASCVD, HF, CKD, and comorbid HF and CKD, as well as a graphical summary of medications used for DCRM.

Details

Database :
OpenAIRE
Journal :
Journal of diabetes and its complications, vol 36, iss 2
Accession number :
edsair.doi.dedup.....044f7715c68543ae6394b075ee1271a8